Fig. 2From: Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapyKaplan-Meier analysis of overall survival of 23 patients treated with TT and CKI therapyBack to article page